Stockscreener 앱 받기
11.23
0.36%
0.04
시간 외 거래:
11.23
Keros Therapeutics Inc 주식(KROS)의 최신 뉴스
Duchenne Muscular Dystrophy Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 75+ Leading Players Wheeling the Therapeutics Landscape - GlobeNewswire Inc.
KROS Turns to Next Wave of TGF-Beta Muscle Therapies - The Globe and Mail
Should You Buy KROS After Q1 Miss and Takeda Deal Reset? - The Globe and Mail
KROS Stock Guide to Rinvatercept in DMD and ALS for 2026 - The Globe and Mail
Keros Therapeutics (KROS) Q1 2026 Disappoints — EPS $-1.21 Below $-1.04 ViewsQuarterly Earnings Report - Newser
Keros Therapeutics, Inc. (KROS) reports Q1 loss, misses revenue estimates - MSN
Lexington, MA Biopharma Co. Reports Q1 2026 Financials, Makes R&D Plans - Streetwise Reports
Lexington, MA Biotech Pushes DMD Phase 2 Start to 3Q26 on Regulatory Hurdles - Streetwise Reports
Wedbush Maintains Keros Therapeutics(KROS.US) With Hold Rating, Maintains Target Price $16 - Moomoo
Director at Keros Therapeutics (KROS) buys 1,000 shares under 10b5-1 plan - Stock Titan
Why is Keros Therapeutics (KROS) up 2.5% since last earnings report? - MSN
Keros Therapeutics, Inc.common stock (NQ: KROS - The Chronicle-Journal
Earnings Release: Here's Why Analysts Cut Their Keros Therapeutics, Inc. (NASDAQ:KROS) Price Target To US$21.20 - Yahoo Finance
How Much Upside is Left in Keros Therapeutics (KROS)? Wall Street Analysts Think 34.24% - MSN
Truist Financial Maintains Keros Therapeutics(KROS.US) With Buy Rating - Moomoo
A Quick Look at Today's Ratings for Keros Therapeutics(KROS.US), With a Forecast Between $20 to $20 - Moomoo
Nantahala's 1.36M-share stake in Keros Therapeutics (NASDAQ: KROS) - Stock Titan
Keros Q1 Loss Wider Than Expected, Revenues Plunge Year Over Year - The Globe and Mail
Keros Therapeutics Reports Q1 2026 Financial Results: Net Loss, Cash Position, and R&D Updates - Minichart
Keros Therapeutics Releases Q1 2026 Financial Results - AlphaStreet
KROS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Cellectar Biosciences Q1 2026: Loss Narrows 29.6% to -$1.33/Share - AlphaStreet
Keros Therapeutics, Inc. (KROS) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Keros Therapeutics (KROS) swings to Q1 2026 loss as Takeda revenue steps down - Stock Titan
Keros Therapeutics 1Q 2026: Revenue $367K, EPS ($1.21) — 10-Q Summary - TradingView
Takeda to advance Keros anemia drug to Phase 3 as Q1 swings to $23.7M loss - Stock Titan
Keros Therapeutics Reports Recent First Quarter 2026 Financial Results - marketscreener.com
Keros (NASDAQ: KROS) swings to Q1 2026 loss as Takeda license boost fades - Stock Titan
KROS stock: Does the Takeda deal lower dilution risk in 2026? - MSN
TradingKey - TradingKey
Top iBio (IBIO) Competitors 2026 - MarketBeat
KROS (Keros Therapeutics) Q4 earnings miss: EPS $-0.86 vs estimate $-0.64, stock slides 1.19%.Decline Risk - newser.com
What Keros Therapeutics (KROS) does that makes it resilient (Flat) 2026-05-06Top Analyst Picks - newser.com
(KROS) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Keros Therapeutics, Inc. (NASDAQ:KROS) Given Average Rating of "Hold" by Analysts - MarketBeat
Sarcopenia Market Insights Highlight Expanding Outlook Till 2034, DelveInsight Evaluates | TNF Pharma, Lipocine, Biophytis, ImmunoForge, Rejuvenate Biomed, Keros Therapeutics, BPGbio, Oncocross, Mirsc - Barchart.com
Insmed (INSM) soars 5.5%: Is further upside left in the stock? - MSN
Keros Therapeutics (KROS) to Release Quarterly Earnings on Tuesday - MarketBeat
Keros gains Orphan Drug designation for Duchenne muscular dystrophy asset - MSN
Responsive Playbooks and the KROS Inflection - Stock Traders Daily
KROS|Keros Therapeutics Inc|Price:11.510|Chg%:-0.05 - TradingKey
ADAR1 Capital Management urges Keros Therapeutics for board change - MSN
Keros Therapeutics (KROS) Business Update | Q4 2025: Earnings UnderperformShared Buy Zones - Cổng thông tin điện tử tỉnh Lào Cai
0.98%
0.12%
자본화:
|
볼륨(24시간):